Elder Neutraciticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit 128.92%
(FY 2021)
- Ebitda 146.59%
(FY 2021)
- Net Worth 44.22%
(FY 2021)
- Total Assets 1261.47%
(FY 2021)
About Elder Neutraciticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shalini Kumar, Karan Kumar, and Anmol Bhargava serve as directors at the Company.
- CIN/LLPIN
U15400MH2015PTC261070
- Company No.
261070
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Elder Neutraciticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shalini Kumar  | Director | 19-Jan-2015 | Current |
| Karan Kumar | Director | 19-Jan-2015 | Current |
| Anmol Bhargava | Additional Director | 05-Jul-2019 | Current |
Financial Performance and Corporate Structure Insights of Elder Neutraciticals.
Elder Neutraciticals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 128.92% increase in profit. The company's net worth Soared by an impressive increase of 44.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elder Neutraciticals?
In 2021, Elder Neutraciticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elder Equipments Private LimitedActive 10 years 4 monthsShalini Kumar and Karan Kumar are mutual person
Aelius Pharma Private LimitedActive 11 years 3 monthsShalini Kumar and Karan Kumar are mutual person
- Orbit Multitech Private Limited (Alteration)Active 24 years 2 months
Karan Kumar and Anmol Bhargava are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elder Neutraciticals?
Unlock and access historical data on people associated with Elder Neutraciticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elder Neutraciticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elder Neutraciticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
